Comment on: Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: An 8 week controlled trial [8]

Rheumatology

Volumn 47, Issue 3, 2008, Pages 381-382

  Kotyla, P J ^a  

^a CHAPEL ALLERTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; CLINICAL TRIAL; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; HUMAN; IMMUNOMODULATION; LETTER; PLEIOTROPY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; VASCULAR DISEASE; VASODILATATION;

CONTROLLED CLINICAL TRIALS AS TOPIC; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PYRROLES; TREATMENT OUTCOME; VASODILATION;

EID: 39449092813     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem381     Document Type: Letter

References (5)

1. Ferreira GA, Navarro TP, Telles RW, Andrade LEC, Sato I. Atorvastatin therapy improves endothelial-dependent vasodilatation in patients with systemic lupus erythematosus: An 8 weeks controlled trial. Rheumatology 2007;46:1560-5.
2. Pierre-Paul D, Gathan V. Noncholesterol-lowering effects of statins. Vasc Endovasc Surg 2003;37:301-13.
3. Sparrow CP, Burton CA, Hernandez M et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterd lowering. Arteriosci Thromb Vas Biol 2001;21:115-21.
4. Kotyla P, Sliwinska-Kotyla. B. Therapeutic potential of HMG-CoA reductase inhibitors (statins) in systemic lupus erythematosus In: Steward TI, ed. Progress in systemic lupus erythematosus research. Nova Science Publishers 2007 in press.
5. Kotyla PJ, Sliwinska-Kotyla B, Kucharz EJ. TNF alpha as a potential target in the treatment of SLE: A role of HMG-CoA reductase inhibitor simvastatin. J Rheumatol 2006;33:2361.